Chandan Healthcare Ltd

- Chandan Healthcare Limited has already raised funds through preferential shares amounting to INR104 crores. - As of now, INR26 crores (25% of the preferential shares) has been received, with the balance expected within the next year. - This fundraising is considered sufficient for the company's expansion plans over the next year. - Management does not anticipate any further equity dilution or fundraising through equity for the next two to three years. - There is no mention of any planned or ongoing debt fundraising in the provided content. - Overall, the company is well-capitalized for near-term expansion and does not foresee additional fundraising needs imminently.

- Planned investment of INR 100 crores over the next three years for setting up 100 new laboratories. - Each laboratory requires approximately INR 1 crore in capex (INR 50-75 lakhs for setup plus INR 50 lakhs for machines). - Preferential shares of INR 104 crores have been raised, with INR 26 crores already received, to fund expansion smoothly. - Expansion plan includes launching 13 new labs, 3 comprehensive centres, a PET scan facility at Gorakhpur, and a genome lab at Lucknow in the coming year. - Central lab and wellness centre to begin in H1 FY27 at Jankipuram, Lucknow, expected to be the largest lab in Uttar Pradesh. - The company is focusing on both owned labs (capex-heavy) and franchisee collection points (minimal capex). - Expansion involves not only metropolitan cities but also Tier 2, 3, and 4 cities across 13 states.

- Chandan Healthcare Limited expects top-line growth much higher than 30% in the next financial year (FY’27), surpassing current projections. - New government contracts, including a INR55 crore per year project in Punjab and Guwahati, will act as significant growth drivers. - Expansion plans include launching 18 new labs and 37 comprehensive centers in the current year, with further scale-up in the next two to three years. - The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. - A strategic focus on Tier 2, 3, and 4 cities, which contribute 90% of the business, will support volume growth. - Growth is supported by a robust team and preferential shares funding of INR104 crores, ensuring smooth expansion. - Quarterly incremental growth is expected, with visible improvements in Q4 FY’27 and beyond.

- The company expects revenue growth significantly higher than 30% in FY'27, surpassing previous projections. - Expansion plans include government contracts worth INR55-52 crores annually (Punjab and Guwahati project), acting as a game changer. - EBITDA margins are anticipated to improve quarter-on-quarter, with current diagnostic EBITDA margins already above 30%; aiming to increase overall margins to 35%+. - EBITDA margins for B2C business are around 35-40%, considered sustainable, though consolidated margins average 30-35% due to B2B and B2G segments. - Positive net cash inflow from operations is expected with improving working capital. - No further equity dilution is anticipated for capex over the next 2-3 years due to preferential shares funds already raised. - PAT and bottom line are expected to reflect significant growth aligned with revenue and contract wins starting next year.

- Chandan Healthcare Limited has secured significant government contracts, including a major contract from Punjab and Guwahati, valued at approximately INR 55 crores annually. - The company has a fully subscribed preferential shares issuance of INR 104 crores, of which INR 26 crores (25%) has been received, with the balance expected within the next year to fund expansion plans. - Expansion plans include launching 18 new labs and 7 comprehensive centers this year, with an additional 13 labs and 3 comprehensive centers planned next year. - New labs are starting soon in multiple cities: Mumbai, Kolkata, Chandigarh, Ahmedabad, Surat, Vadodara, Guwahati, Kurukshetra, and Kota. - The orderbook includes setting up a genome lab at Lucknow and a PET scan facility at Gorakhpur, along with wellness and central labs, particularly the largest central lab in Uttar Pradesh at Jankipuram, Lucknow. Overall, the order pipeline is robust and well-funded, supporting smooth expansion.